A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS

Trial Profile

A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriasis; Vasculitis
  • Focus Biomarker; Therapeutic Use
  • Acronyms VIP-U
  • Most Recent Events

    • 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 16 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top